Ginkgo Bioworks Holdings DNA
NYSE DNA
$6.80 -0.14 (-2.09%)
As of: Sep 9, 2026 · 3:59 PM EDT

Ginkgo Bioworks Holdings (DNA) Capital Expenditures Growth (3y) (2023 - 2026)

Analysis

Ginkgo Bioworks Holdings (DNA) Capital Expenditures Growth (3y) (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex Growth (3y) (Qtr)
1 Iqvia Holdings 44.06 Bn 42.11 Bn 1.44 Bn 7.36%
2 Medpace Holdings 16.50 Bn 16.00 Bn 201.64 Mn 41.46%
3 Charles River Laboratories International 13.77 Bn 13.62 Bn 452.07 Mn -22.72%
4 Icon 12.62 Bn 11.69 Bn 479.29 Mn -9.70%
5 Fortrea Holdings 1.68 Bn 1.51 Bn 139.20 Mn -2.13%
6 Evotec SE 661.34 Mn 235.46 Mn - -
7 Ginkgo Bioworks Holdings 442.79 Mn 358.26 Mn 18.44 Mn -42.16%
8 Champions Oncology 72.49 Mn 72.62 Mn 7.03 Mn -32.00%
9 MindWalk Holdings 61.66 Mn 53.38 Mn 1.82 Mn 71.36%
10 VivoSim Labs 1.47 Mn 1.47 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -42.16%
Mar 31, 2026 -53.67%
Dec 31, 2025 -94.20%
Jun 30, 2025 -84.17%
Mar 31, 2025 28.65%
Dec 31, 2024 38.92%
Sep 30, 2024 40.52%
Jun 30, 2024 4.00%
Mar 31, 2024 -32.62%
Dec 31, 2023 -43.80%